AI platform provides easy access to eye disease diagnosis for OSF patients with diabetes
- AI platform can provide accurate diagnosis of diabetic retinopathy within a few minutes.
- Yearly LumineticsCore exams provide early identification of retinopathy to prevent vision loss.
- 25% of nearly 1,500 OSF patients with diabetes have tested positive for diabetic retinopathy.
Digital Diagnostics, a leading artificial intelligence (AI) diagnostic healthcare company’s flagship product, LumineticsCore™ (formerly IDx-DR), is increasing access to innovative care at OSF HealthCare for people living with diabetes. LumineticsCore is an FDA cleared, autonomous AI platform to detect diabetic retinopathy during a patient visit by analyzing retinal images for signs of disease without the need for a specialist to interpret the images.
OSF HealthCare initially launched LumineticsCore at eight sights, which have been operating for a full year. Based on the successful integration of LumineticsCore at the initial sites, OSF expanded the use of LumineticsCore to 24 additional sites that have now been operating for nine months. Using LumineticsCore, OSF HealthCare has been able to inform 25% of nearly 1,500 patients with diabetes, that they tested positive for diabetic retinopathy (DR). Without convenient access to the exam, many of those patients might not have been tested for DR, the leading cause of blindness for adults in the U.S.
Digital Diagnostics is committed to bringing high-quality AI diagnosis to the point-of-care, starting with the diabetic retinal exam to prevent vision loss and blindness for people living with diabetes. “We are always seeking new ways to innovate and improve access to cutting-edge diagnostics for our patients so we can help them better manage their health conditions, including diabetes which impacts nearly 66,000 OSF patients,” said Mark Meeker, DO, vice president of Community Medicine for OSF HealthCare.
We are always seeking new ways to innovate and improve access to cutting-edge diagnostics for our patients so we can help them better manage their health conditions, including diabetes which impacts nearly 66,000 OSF patients. Mark Meeker, DO, vice president of Community Medicine for OSF HealthCare.
“Working with Digital Diagnostics allows us to offer an expanded set of services to our patients, while empowering our clinicians to help their patients decrease disease progression through prevention, not just through treatment.”
“The positive impact our partnership with OSF HealthCare is having in the lives of patients’ is exactly in line with our mission,” says Digital Diagnostics’ Senior Vice President of Commercial, Sean Murnane. “Offering LumineticsCore to patients in a setting where they are already comfortable, coupled with the high-quality care offered at OSF, furthers our organizations’ collective goal of improving patient outcomes.”